CD274 and colorectal carcinoma: The mechanistic rationale of aspirin plus FOLFOX sequential combination therapy in suppressing BIRC7/Livin and reactivating DARC and PD-L1 expression underscores the potential of aspirin combination therapy in future CRC management.